Cargando…
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases
Objective. We assess the behavior of serum concentrations of HE4 marker in female carriers of BRCA1 and assess the diagnostic usefulness of HE4 in ovarian and endometrial cancer. Methods. A total of 619 women with BRCA1 gene mutation, ovarian, endometrial, metastatic, other gynecological cancers, or...
Autores principales: | Chudecka-Głaz, Anita, Cymbaluk-Płoska, Aneta, Strojna, Aleksandra, Menkiszak, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5274692/ https://www.ncbi.nlm.nih.gov/pubmed/28182133 http://dx.doi.org/10.1155/2017/9792756 |
Ejemplares similares
-
HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases
por: Chudecka-Głaz, Anita, et al.
Publicado: (2014) -
Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
por: Chudecka-Głaz, Anita, et al.
Publicado: (2018) -
Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016) -
Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016) -
Ectopic pregnancy treatment by combination therapy
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2016)